

1994, now pending, which is a continuation-in-part of U.S. Serial No. 08/246,006, filed May 19, 1994, now abandoned, which is a continuation-in-part of U.S. Serial No. 08/142,669, filed October 25, 1993, now abandoned, the contents of which are hereby incorporated by reference into the present disclosure.

At page 6, line 4, change "Figure 1 shows" to --Figures 1A and 1B show--.

At page 6, line 6, change "Figure 1" to --Figures 1A and 1B--.

At page 6, line 12, change "Figure 2 shows" to --Figures 2A through 2D show--.

At page 6, line 13, change "Figure 3 shows" to --Figures 3A through 3D show--.

At page 6, line 28 through page 7, line 11, delete the description of Figures 5A and 5B.

At page 7, lines 12 through 17, delete the description of Figures 6A and 6B.

At page 7, line 18, change "Figure 7 shows" to --Figures 5A through 5I show--.

At page 7, line 19, insert --nine different-- after "in".

At page 7, line 31, change "Figure 8" to --Figure 6--.

At page 8, lines 8 through 28, delete the description of Figure 9.

At page 8, line 29, change "Figures 10A and 10B" to --Figures 7A and 7B--.

At page 9, line 11, change "11A through 11C" to --8A through 8C--.

At page 9, line 17, change "11A" to --8A--.

At page 9, line 23, change "12" to --9--.

At page 9, line 24, change "11B" to --8B--.

At page 9, line 31, change "11C" to --8C--.

At page 10, line 3, change "12" to --9--.

At page 10, lines 17 through 33, delete the description of Figure 13.

At page 11, line 1, change "Figure 14 shows" to --Figures 10A and 10B show--.

At page 11, line 2, insert --two-- after "on".

At page 11, line 16, change "15" to --11--.

At page 11, line 25, change "16A and 16B" to --12A and 12B--.

At page 11, line 35, change "6A" to --12A--.

At page 12, line 2, change "6B" to --12B--.

At page 17, line 20, change "Figure 3" to --Figures 3A through 3D--.

At page 17, line 22, change "Figure 2" to --Figures 2A through 2D--.

At page 17, line 23, change "Figure 3" to --Figures 3A through 3D--.

At page 19, line 7, delete "coding sequence of" and insert therefor --amino acid sequence encoded by--.

OK — At page 19, line 8, delete "Table I" and insert therefor --Table 1--.

At page 20, line 3, delete "V\*SHR PGSR\* LLGSG DTLRS GWERA FHDGD TLPWI GSQTA FRVTA".

OK — At page 33, line 1, change "Table I" to --Table 1--.

At page 37, line 18, delete "(Figure 5)".

At page 37, line 20, delete "(Figure 3)".

At page 37, line 26, delete "(Figure 5)".

At page 38, line 7, delete "(Figure 6, panel C)".

At page 38, lines 7-8, delete "(Figure 6, panel A)".

At page 38, lines 8-9, delete "(Figure 6, panel B)".

At page 38, line 14, delete "(Figure 5A)".

At page 38, line 33, change "(Figure 7)" to --(Figures 5A through 5I)--.

At page 40, line 12, change "(Figure 8)" to --(Figure 6)--.

At page 41, line 2, delete "(Figure 9, lanes 1, 2, 4, 5).", and replace with --RT-

PCR was carried out using equal RNA concentrations and primers specific for recombinant p53 message. PCR amplification was for 30 cycles at 94°C 1 min., 55°C 1.5 min., 72°C 2 min., and a 10 min., 72°C final extension period in an Omnigen thermocycler (Hybaid). The PCR primers used were a 5' Tripartite Leader cDNA (5'-CGCCACCGAGGGACCTGAGCGAGTC-3', SEQ ID NO:1) and a 3' p53 primer (5'-TTCTGGGAGGGACAGAAGA-3', SEQ ID NO:2).

At page 41, line 4, delete "(Figure 9, lanes 3 and 6)".

At page 41, line 6, delete "(Figure 9, lanes 7-9)".

At page 41, line 6, delete "(Figure 9, lane 10)".

At page 41, line 25, change "10A" to --7A--.

At page 41, line 29, change "10A" to --7A--.

At page 42, line 3, change "10B" to --7B--.

At page 42, line 7, change "10B" to --7B--.

*me* At page 45, line 1, change "Figure 10" to --Figures 7A and 7B--.

At page 46, line 32, change "Figures 11 and 12" to --Figures 8 and 9--.

At page 46, line 26, change "Figure 11" to --Figure 8--.

At page 52, line 26, delete "As shown in Figure 13," and change "directs" to --directed--.

At page 52, line 28, delete "(Figure 13)".

At page 53, line 11, change "Figure 14" to --Figures 10A and 10B--.

At page 54, line 5, change "Figure 16" to --Figures 12A and 12B--.

**In the Claims:**

Please amend claims 16, 18, 23, and 26 as follows:

*C3* *Sub D1* 16. (Twice amended) A method of treating a pathology in an animal or mammal caused by the absence of a tumor suppressor gene or the presence of a pathologically mutated tumor suppressor gene, the method comprising administering to the animal or mammal an effective amount of a recombinant adenovirus expression vector comprising: a) a partial or total deletion of a protein IX-encoding DNA sequence, and b) a gene encoding a foreign functional protein having a tumor suppressive function, under suitable conditions.

*C4* 18. (Twice amended) A method of gene therapy comprising administering to a subject an effective amount of a recombinant adenovirus expression vector comprising: a) a partial or total deletion of a protein IX-encoding DNA sequence, and b) a gene encoding a foreign functional protein having a tumor suppressive function.

*C5* 23. (Once amended) The method of claim 21, wherein the tumor is non-small cell lung cancer, small cell lung cancer, hepatocarcinoma, melanoma, retinoblastoma, breast tumor, colorectal carcinoma, leukemia, lymphoma, brain tumor, cervical carcinoma, sarcoma, prostate tumor, bladder tumor, tumor of the reticuloendothelial tissues, Wilm's tumor,